Elizabeth Steiner

Elizabeth Steiner Elmazahi serves as a Procurement Analyst responsible for managing the acquisition lifecycle for complex scientific and pharmaceutical products within a federal entity focused on health innovation. She plays a critical role in translating technical requirements into compliant solicitation documents, evaluating vendor proposals against performance and regulatory standards, and ensuring alignment with federal procurement regulations under the FAR. Her work supports mission-critical procurement of biopharmaceuticals, research services, and advanced manufacturing capabilities, often involving high-compliance environments requiring strict adherence to FDA and NIH guidelines. While specific contractor names are not disclosed, her procurement patterns reflect consistent engagement with specialized manufacturers and R&D firms possessing GMP certification, cGMP compliance, and advanced bioprocessing capabilities. She fosters collaborative relationships with vendors capable of meeting stringent quality control, supply chain integrity, and regulatory documentation requirements, often working through competitive sealed bidding and request for proposal (RFP) mechanisms to ensure transparency and value. Elizabeth demonstrates a strong preference for open competition, with 100% of her acquisitions conducted without set-aside designations, indicating a focus on technical merit and capability over socioeconomic categorization. Her approach prioritizes mission need and product efficacy, ensuring that procurement decisions are driven by scientific and operational requirements rather than socioeconomic preferences. Her primary procurement focus centers on NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325414 (Biological Product Manufacturing), with significant activity in NAICS 541714 (Research and Development in Biotechnology). She routinely procures active pharmaceutical ingredients, monoclonal antibody production systems, clinical-stage biologics, and preclinical research services, demonstrating deep expertise in biopharmaceutical development, process validation, and GxP-compliant supply chains. Her technical domain knowledge ensures acquisitions align with evolving regulatory landscapes in biotechnology and life sciences.